IP Library › Granted Patent US 12,576,066
Granted Patent B2
US 12,576,066 · App. 19/029,360 · Granted Mar 17, 2026

Methods and compositions for treatment of mydriasis

Inventors: Mina Sooch (Bloomfield, MI); Alan R. Meyer (North Riverside, IL); Konstantinos Charizanis (Ypsilanti, MI); Bernhard Hoffmann (Lake Forest, IL); William H. Pitlick (Seattle, WA)
Assignee: Opus Genetics, Inc.
A61K31/417A61K31/4178A61P27/08A61P27/10A61K9/0048A61K9/08A61K47/12A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,576,066
App. No.
19/029,360
Granted
Mar 17, 2026
Kind
B2
Abstract

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.

Claims (54)

1 . A method of treating mydriasis in a human patient due to said patient having received tropicamide, phenylephrine, or a pharmaceutically acceptable salt thereof, or a combination of hydroxyamphetamine hydrobromide and tropicamide or a pharmaceutically acceptable salt thereof, comprising administering to an eye of the human patient in need thereof a dosage of phentolamine mesylate to thereby treat the mydriasis, wherein the dosage is topically administered to the patient's eye as one eye drop of a 1% (w/w) phentolamine mesylate solution.

2 . The method of claim 1 , wherein the mydriasis is due to the patient having received tropicamide or a pharmaceutically acceptable salt thereof.

3 . The method of claim 1 , wherein the mydriasis is due to the patient having received phenylephrine or a pharmaceutically acceptable salt thereof.

4 . The method of claim 1 , wherein the mydriasis is due to the patient having received a combination of hydroxyamphetamine hydrobromide and tropicamide or a pharmaceutically acceptable salt thereof.

5 . The method of claim 1 , wherein a therapeutic benefit is observed within 1 hour after administering the dosage of phentolamine mesylate.

6 . The method of claim 2 , wherein a therapeutic benefit is observed within 1 hour after administering the dosage of phentolamine mesylate.

7 . The method of claim 3 , wherein a therapeutic benefit is observed within 1 hour after administering the dosage of phentolamine mesylate.

8 . The method of claim 1 , wherein the eye drop is a liquid aqueous ophthalmic formulation.

9 . The method of claim 2 , wherein the eye drop is a liquid aqueous ophthalmic formulation.

10 . The method of claim 3 , wherein the eye drop is a liquid aqueous ophthalmic formulation.

11 . The method of claim 1 , wherein the patient experiences at least a 2 mm reduction in pupil diameter when measured under photopic conditions relative to the diameter of the patient's pupil under the same photopic conditions but not having received said dosage.

12 . The method of claim 1 , wherein at two hours after the dosage of phentolamine mesylate is administered to the patient's eye, the patient experiences at least a 1 mm reduction in pupil diameter when measured under photopic conditions relative to the diameter of the patient's pupil under the same photopic conditions but not having received said dosage.

13 . The method of claim 2 , wherein at two hours after the dosage of phentolamine mesylate is administered to the patient's eye, the patient experiences at least a 1 mm reduction in pupil diameter when measured under photopic conditions relative to the diameter of the patient's pupil under the same photopic conditions but not having received said dosage.

14 . The method of claim 3 , wherein at two hours after the dosage of phentolamine mesylate is administered to the patient's eye, the patient experiences at least a 1 mm reduction in pupil diameter when measured under photopic conditions relative to the diameter of the patient's pupil under the same photopic conditions but not having received said dosage.

15 . The method of claim 1 , wherein the patient experiences an increase in eye redness of no more than two grades measured using the CCLRU Redness Grading Scale compared to the patient's level of eye redness without receiving said dosage of phentolamine mesylate.

16 . The method of claim 2 , wherein the patient experiences an increase in eye redness of no more than two grades measured using the CCLRU Redness Grading Scale compared to the patient's level of eye redness without receiving said dosage of phentolamine mesylate.

17 . The method of claim 3 , wherein the patient experiences an increase in eye redness of no more than two grades measured using the CCLRU Redness Grading Scale compared to the patient's level of eye redness without receiving said dosage of phentolamine mesylate.

18 . The method of claim 1 , wherein human patient is a pediatric human patient.

19 . The method of claim 2 , wherein human patient is a pediatric human patient.

20 . The method of claim 3 , wherein human patient is a pediatric human patient.

21 . A method of treating mydriasis in a human patient due to said patient having received tropicamide, phenylephrine, or a pharmaceutically acceptable salt thereof, or a combination of hydroxyamphetamine hydrobromide and tropicamide or a pharmaceutically acceptable salt thereof, comprising administering to an eye of the human patient in need thereof a dosage of phentolamine mesylate to thereby treat the mydriasis, wherein the dosage is topically administered to the patient's eye as one eye drop of a 1% (w/v) phentolamine mesylate aqueous solution.

22 . The method of claim 21 , wherein the mydriasis is due to the patient having received tropicamide or a pharmaceutically acceptable salt thereof.

23 . The method of claim 21 , wherein the mydriasis is due to the patient having received phenylephrine or a pharmaceutically acceptable salt thereof.

24 . The method of claim 21 , wherein the mydriasis is due to the patient having received a combination of hydroxyamphetamine hydrobromide and tropicamide or a pharmaceutically acceptable salt thereof.

25 . The method of claim 21 , wherein a therapeutic benefit is observed within 1 hour after administering the dosage of phentolamine mesylate.

26 . The method of claim 21 , wherein at two hours after the dosage of phentolamine mesylate is administered to the patient's eye there is at least a 30% reduction in pupil diameter in said eye of the patient measured under photopic conditions.

27 . The method of claim 21 , wherein the eye drop is a liquid aqueous ophthalmic formulation.

28 . The method of claim 21 , wherein at two hours after the dosage of phentolamine mesylate is administered to the patient's eye, the patient experiences at least a 1 mm reduction in pupil diameter when measured under photopic conditions relative to the diameter of the patient's pupil under the same photopic conditions but not having received said dosage.

29 . The method of claim 21 , wherein the patient experiences an increase in eye redness of no more than two grades measured using the CCLRU Redness Grading Scale compared to the patient's level of eye redness without receiving said dosage of phentolamine mesylate.

30 . The method of claim 21 , wherein human patient is a pediatric human patient.

31 . A method of treating pharmacologically-induced mydriasis in a human patient due to said patient having received one or more of tropicamide, phenylephrine or a pharmaceutically acceptable salt thereof, or a combination of hydroxyamphetamine hydrobromide and tropicamide or a pharmaceutically acceptable salt thereof, where said patient does not have ocular inflammation, comprising administering to an eye of the human patient in need thereof a dosage of a phentolamine mesylate solution to thereby treat the mydriasis, wherein the dosage is topically administered to the patient's eye as an eye drop, where each eye drop contains from about 0.4 mg to about 0.6 mg of phentolamine mesylate.

32 . The method of claim 31 , wherein said ocular inflammation is iritis.

33 . The method of claim 32 , wherein at one hour after the dosage of phentolamine mesylate is administered to the patient's eye, the baseline in mean pupil diameters was statistically significant (p<0.01) for subjects treated the phentolamine mesylate solution relative to patients under the same photopic conditions but not having received said dosage.

34 . The method of claim 31 , wherein the patient experiences at least a 1 mm reduction in pupil diameter when measured under photopic conditions relative to the diameter of the patient's pupil under the same photopic conditions but not having received said dosage when measured two hours after the dosage.

35 . The method of claim 32 , wherein the patient experiences at least a 1 mm reduction in pupil diameter when measured under photopic conditions relative to the diameter of the patient's pupil under the same photopic conditions but not having received said dosage when measured two hours after the dosage.

36 . The method of claim 33 , wherein the patient experiences at least a 1 mm reduction in pupil diameter when measured under photopic conditions relative to the diameter of the patient's pupil under the same photopic conditions but not having received said dosage when measured two hours after the dosage.

37 . The method of claim 31 , wherein said phentolamine mesylate solution is administered to the eye of the patient once the patient has completed an eye examination in which the one or more of tropicamide, phenylephrine, or a pharmaceutically acceptable salt thereof was administered to the patient's eye.

38 . The method of claim 32 , wherein said patient received tropicamide or a pharmaceutically acceptable salt thereof.

39 . The method of claim 32 , wherein said patient received phenylephrine or a pharmaceutically acceptable salt thereof.

40 . The method of claim 32 , wherein said patient received a combination of hydroxyamphetamine hydrobromide and tropicamide or a pharmaceutically acceptable salt thereof.

41 . The method of claim 32 , wherein said phentolamine mesylate solution comprises: (a) about 0.1% (w/v) to about 2% (w/v) of phentolamine mesylate; (b) about 1% (w/v) to about 6% (w/v) of at least one polyol compound selected from the group consisting of mannitol, glycerol, and propylene glycol; (c) about 1 mM to about 6 mM of an alkali metal acetate; and (d) water; wherein the solution has a pH in the range of 4 to 6.

42 . The method of claim 32 , wherein said phentolamine mesylate solution comprises: (a) about 0.5% (w/v) to about 2% (w/v) of phentolamine mesylate; (b) about 1% (w/v) to about 6% (w/v) of at least one polyol compound selected from the group consisting of mannitol, glycerol, and propylene glycol; (c) about 1 mM to about 6 mM of an alkali metal acetate; and (d) water; wherein the solution has a pH in the range of 4.5 to 5.5.

43 . The method of claim 32 , wherein said phentolamine mesylate solution comprises: (a) about 0.25% (w/v) to about 2% (w/v) of phentolamine mesylate; (b) about 3% (w/v) to about 5% (w/v) of mannitol; (c) about 2 mM to about 4 mM of sodium acetate; and (d) water; wherein the solution has a pH in the range of 4.5 to 5.2.

44 . The method of claim 32 , wherein said phentolamine mesylate solution comprises: (a) about 0.5% (w/v) to about 2% (w/v) of phentolamine mesylate; (b) about 3% (w/v) to about 5% (w/v) of mannitol; (c) about 2 mM to about 4 mM of sodium acetate; and (d) water; wherein the solution has a pH in the range of 4.6 to 5.2.

45 . The method of claim 32 , wherein said phentolamine mesylate solution comprises: (a) about 0.5% (w/v) to about 1% (w/v) of phentolamine mesylate; (b) about 4% mannitol; (c) about 3 mM sodium acetate; and (d) water; wherein the solution has a pH in the range of 4.6 to 5.2.

46 . The method of claim 32 , wherein said phentolamine mesylate solution comprises: (a) about 0.25% (w/v) to about 2% (w/v) of phentolamine mesylate; (b) about 3% (w/v) to about 5% (w/v) of mannitol; (c) about 1 mM to about 6 mM of sodium acetate; and (d) water; wherein the solution has a pH in the range of 4.5 to 5.2.

47 . The method of claim 32 , wherein said phentolamine mesylate solution comprises: (a) about 1% (w/v) of phentolamine mesylate; (b) about 3% (w/v) to about 5% (w/v) of mannitol; (c) about 2 mM to about 4 mM of a buffer comprising sodium acetate; and (d) water; wherein the solution has a pH in the range of 4.5 to 5.2.

48 . The method of claim 32 , wherein said phentolamine mesylate solution comprises: (a) about 0.25% (w/v) to about 2% (w/v) of phentolamine mesylate; (b) about 3% (w/v) to about 5% (w/v) of mannitol; (c) about 2 mM to about 4 mM of sodium acetate; and (d) water; wherein the solution has a pH in the range of 4.5 to 5.2.

49 . The method of claim 32 , wherein said phentolamine mesylate solution comprises: (a) about 0.5% (w/v) to about 2% (w/v) of phentolamine mesylate; (b) about 3% (w/v) to about 5% (w/v) of mannitol; (c) about 2 mM to about 4 mM of a buffer comprising sodium acetate; and (d) water; wherein the solution has a pH in the range of 4.6 to 5.2 and does not contain any additional component that is a chelating agent.

50 . The method of claim 32 , wherein said phentolamine mesylate solution comprises: (a) about 0.5% (w/v) to about 1% (w/v) of phentolamine mesylate; (b) about 4% mannitol; (c) about 3 mM of a buffer comprising sodium acetate; and (d) water; wherein the solution has a pH in the range of 4.6 to 5.2 and does not contain any additional component that is a chelating agent.

51 . The method of claim 31 , wherein at twenty-four hours after the dosage of phentolamine mesylate is administered to the patient's eye there is a reduction in pupil diameter of said patient measured under photopic conditions relative to the patient under the same photopic conditions but not having received said dosage and said ocular inflammation is iritis.

52 . The method of claim 1 , wherein said phentolamine mesylate solution is characterized by less than 10% by weight of the phentolamine mesylate degrading upon storage at temperature in the range of 2-8° C. for 18 months, 24 months, or 36 months.

53 . The method of claim 21 , wherein said phentolamine mesylate aqueous solution is characterized by less than 10% by weight of the phentolamine mesylate degrading upon storage at temperature in the range of 2-8° C. for 18 months, 24 months, or 36 months.

54 . The method of claim 31 , wherein said phentolamine mesylate solution is characterized by less than 10% by weight of the phentolamine mesylate degrading upon storage at temperature in the range of 2-8° C. for 18 months, 24 months, or 36 months.

Assignments (3)
SECURITY INTEREST Recorded Apr 21, 2026
From: OPUS GENETICS, INC.
To: OPCM SA LLC, AS PURCHASER AGENT FOR THE SECURED PARTIES
Reel/Frame 075478/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2025
From: PITLICK, WILLIAM H.; MEYER, ALAN R.; SOOCH, MINA; CHARIZANIS, KONSTANTINOS; HOFFMAN, BERNHARD
To: OCUPHIRE PHARMA, INC.
Reel/Frame 070775/0436 →
CHANGE OF NAME Recorded Apr 8, 2025
From: OCUPHIRE PHARMA, INC.
To: OPUS GENETICS, INC.
Reel/Frame 070778/0585 →
Continuity (5)
Continuation 17877558 · Jul 29, 2022
Continuation 16841006 · Apr 6, 2020
Continuation PCTUS2019058182 · Oct 25, 2019
Provisional Application 62751391 · Oct 26, 2018
Related Publication 20250161274A1 · May 22, 2025
References Cited (400)
US 4252721A · Silvestrini et al. · 1981 [cited by applicant]
US 4443441A · Galin · 1984 [cited by applicant]
US 4508715A · Booth et al. · 1985 [cited by applicant]
US 4515295A · Dougherty · 1985 [cited by applicant]
US 4590202A · Remy · 1986 [cited by applicant]
US 4629456A · Edwards · 1986 [cited by applicant]
US 4659714A · Watt-Smith · 1987 [cited by applicant]
US 4834727A · Cope · 1989 [cited by applicant]
US 4888344A · Sunagawa et al. · 1989 [cited by applicant]
US 4906613A · Watkins · 1990 [cited by applicant]
US 4938970A · Hustead et al. · 1990 [cited by applicant]
US 5032392A · Varma · 1991 [cited by applicant]
US 5059188A · Goddard · 1991 [cited by applicant]
US 5134124A · Nisato et al. · 1992 [cited by applicant]
US 5149320A · Dhaliwal et al. · 1992 [cited by applicant]
US 5192527A · Abrahmsohn · 1993 [cited by applicant]
US 5261903A · Dhaliwal et al. · 1993 [cited by applicant]
US 5281591A · Burke · 1994 [cited by applicant]
US 5288759A · DeSantis, Jr. · 1994 [cited by applicant]
US 5488050A · Neufeld · 1996 [cited by applicant]
US 5514118A · Kummer et al. · 1996 [cited by applicant]
US 5584823A · Valberg · 1996 [cited by applicant]
US 5591426A · Dabrowski et al. · 1997 [cited by applicant]
US 5627611A · Scheiner · 1997 [cited by applicant]
US 5792767A · Meyer et al. · 1998 [cited by applicant]
US 5885550A · Vallier · 1999 [cited by applicant]
US 5891882A · Meyer et al. · 1999 [cited by applicant]
US 5891913A · Sallmann et al. · 1999 [cited by applicant]
US 5895654A · Hartford et al. · 1999 [cited by applicant]
US 6001845A · Estok · 1999 [cited by applicant]
US 6025396A · Kim et al. · 2000 [cited by applicant]
US 6043224A · Lee et al. · 2000 [cited by applicant]
US 6046207A · Meyer et al. · 2000 [cited by applicant]
US 6051594A · Lowery · 2000 [cited by applicant]
US 6106866A · Ranney · 2000 [cited by applicant]
US 6291466B1 · Gwon et al. · 2001 [cited by applicant]
US 6291498B1 · Horn · 2001 [cited by applicant]
US 6410544B1 · Gwon et al. · 2002 [cited by applicant]
US 6420407B1 · Horn · 2002 [cited by applicant]
US 6432401B2 · Weber et al. · 2002 [cited by applicant]
US 6469065B1 · Garvey et al. · 2002 [cited by applicant]
US 6515006B2 · Horn · 2003 [cited by applicant]
US 6638537B2 · Dennis et al. · 2003 [cited by applicant]
US 6730065B1 · Horn · 2004 [cited by applicant]
US 6730691B1 · Galin · 2004 [cited by applicant]
US 6764678B2 · Weber et al. · 2004 [cited by applicant]
US 6872390B2 · Weber et al. · 2005 [cited by applicant]
US 7229630B2 · Chen et al. · 2007 [cited by applicant]
US 7569230B2 · Chen et al. · 2009 [cited by applicant]
US 7575757B2 · Chen et al. · 2009 [cited by applicant]
US 7868035B2 · Woodward et al. · 2011 [cited by applicant]
US 8299079B2 · Kaufman · 2012 [cited by applicant]
US 8445526B2 · Horn · 2013 [cited by applicant]
US 8524758B2 · Benozzi · 2013 [cited by applicant]
US 8580787B2 · Horn · 2013 [cited by applicant]
US 8597629B1 · Horn · 2013 [cited by applicant]
US 8829037B2 · Sharma · 2014 [cited by applicant]
US 8889112B2 · Horn · 2014 [cited by applicant]
US 8979809B2 · Horn · 2015 [cited by applicant]
US 9089560B2 · Meyer · 2015 [cited by applicant]
US 9789088B2 · Meyer · 2017 [cited by applicant]
US 9795560B2 · Meyer · 2017 [cited by applicant]
US 9867810B1 · Feinbaum et al. · 2018 [cited by applicant]
US 9968594B2 · Horn et al. · 2018 [cited by applicant]
US 9987254B2 · Hernandez et al. · 2018 [cited by applicant]
US 10064818B2 · Horn et al. · 2018 [cited by applicant]
US 10278918B2 · Meyer · 2019 [cited by applicant]
US 10507245B2 · Vejarano Restrepo · 2019 [cited by applicant]
US 10610518B2 · Robinson et al. · 2020 [cited by applicant]
US 10639297B2 · Feinbaum et al. · 2020 [cited by applicant]
US 10772829B2 · Meyer · 2020 [cited by applicant]
US 10993932B2 · Pitlick et al. · 2021 [cited by applicant]
US 11000509B2 · Meyer · 2021 [cited by applicant]
US 11090261B2 · Meyer · 2021 [cited by applicant]
US 11129812B2 · Feinbaum et al. · 2021 [cited by applicant]
US 11278545B2 · Sharma · 2022 [cited by applicant]
US 11285134B2 · Robinson et al. · 2022 [cited by applicant]
US 11400077B2 · Pitlick et al. · 2022 [cited by applicant]
US 11566005B2 · Oniciu · 2023 [cited by applicant]
US 11717510B2 · Meyer · 2023 [cited by applicant]
US 11844858B2 · Meyer · 2023 [cited by applicant]
US 11974986B2 · Feinbaum et al. · 2024 [cited by applicant]
US 11976044B2 · Oniciu · 2024 [cited by applicant]
US 12016841B2 · Pitlick et al. · 2024 [cited by applicant]
US 12201615B2 · Sooch et al. · 2025 [cited by applicant]
US 12201616B2 · Sooch et al. · 2025 [cited by applicant]
US 12350366B2 · Meyer · 2025 [cited by applicant]
US 20020082288A1 · Horn · 2002 [cited by applicant]
US 20020183356A1 · Weber et al. · 2002 [cited by applicant]
US 20020183396A1 · Weber et al. · 2002 [cited by applicant]
US 20020187986A1 · Horn · 2002 [cited by applicant]
US 20030203034A1 · Huth · 2003 [cited by applicant]
US 20030236306A1 · Chen et al. · 2003 [cited by applicant]
US 20040053894A1 · Mazess et al. · 2004 [cited by applicant]
US 20040176408A1 · Horn · 2004 [cited by applicant]
US 20050080056A1 · Horn · 2005 [cited by applicant]
US 20050203099A1 · Chen et al. · 2005 [cited by applicant]
US 20060211753A1 · Horn · 2006 [cited by applicant]
US 20060257388A1 · Knowles · 2006 [cited by applicant]
US 20070049640A1 · Pavliv · 2007 [cited by applicant]
US 20070098748A1 · Chen et al. · 2007 [cited by applicant]
US 20080020076A1 · Jhamandas et al. · 2008 [cited by applicant]
US 20080039507A1 · Woodward et al. · 2008 [cited by applicant]
US 20080199537A1 · Bhagat et al. · 2008 [cited by applicant]
US 20090131303A1 · Hong et al. · 2009 [cited by applicant]
US 20090220618A1 · Xia et al. · 2009 [cited by applicant]
US 20090232763A1 · Kabra et al. · 2009 [cited by applicant]
US 20100029663A1 · Horn · 2010 [cited by applicant]
US 20100143419A1 · McAffer et al. · 2010 [cited by applicant]
US 20100324031A1 · Kabra · 2010 [cited by applicant]
US 20110152274A1 · Kaufman · 2011 [cited by applicant]
US 20110178147A1 · Likitlersuang et al. · 2011 [cited by applicant]
US 20120136072A1 · Mosher et al. · 2012 [cited by applicant]
US 20120149748A1 · Shanler et al. · 2012 [cited by applicant]
US 20120208858A1 · Shanler et al. · 2012 [cited by applicant]
US 20120238615A1 · Chow et al. · 2012 [cited by applicant]
US 20120277239A1 · Horn et al. · 2012 [cited by applicant]
US 20130029919A1 · Gore et al. · 2013 [cited by applicant]
US 20130096131A1 · Sharma · 2013 [cited by applicant]
US 20130143938A1 · Horn · 2013 [cited by applicant]
US 20130172357A1 · Horn · 2013 [cited by applicant]
US 20140024642A1 · Vejarano Restrepo · 2014 [cited by applicant]
US 20140221445A1 · Meyer · 2014 [cited by applicant]
US 20140221446A1 · Meyer · 2014 [cited by applicant]
US 20150150848A1 · Horn · 2015 [cited by applicant]
US 20160008278A1 · Horn et al. · 2016 [cited by applicant]
US 20160008337A1 · Horn et al. · 2016 [cited by applicant]
US 20160051515A1 · Meyer · 2016 [cited by applicant]
US 20170065664A1 · Russ · 2017 [cited by applicant]
US 20180207136A1 · Feinbaum et al. · 2018 [cited by applicant]
US 20180221274A1 · Meyer · 2018 [cited by applicant]
US 20180221340A1 · Meyer · 2018 [cited by applicant]
US 20190008832A1 · Pinelli · 2019 [cited by applicant]
US 20190254963A1 · Meyer · 2019 [cited by applicant]
US 20190321337A1 · Robinson et al. · 2019 [cited by applicant]
US 20190358152A1 · Meyer · 2019 [cited by applicant]
US 20200246310A1 · Pitlick et al. · 2020 [cited by applicant]
US 20200253931A1 · Pitlick et al. · 2020 [cited by applicant]
US 20210338638A1 · Meyer · 2021 [cited by applicant]
US 20210346349A1 · Pitlick et al. · 2021 [cited by applicant]
US 20210346350A1 · Pitlick et al. · 2021 [cited by applicant]
US 20210369686A1 · Bodmeier et al. · 2021 [cited by applicant]
US 20220175668A1 · Meyer · 2022 [cited by applicant]
US 20220175734A1 · Sambursky et al. · 2022 [cited by applicant]
US 20220226287A1 · Pitlick et al. · 2022 [cited by applicant]
US 20220257593A1 · Sambursky et al. · 2022 [cited by applicant]
US 20230032637A1 · Sooch et al. · 2023 [cited by applicant]
US 20230040217A1 · Sooch et al. · 2023 [cited by applicant]
US 20240050412A1 · Meyer · 2024 [cited by applicant]
US 20240216334A1 · Pepose et al. · 2024 [cited by applicant]
US 20240382462A1 · Robinson et al. · 2024 [cited by applicant]
US 20250161275A1 · Sooch · 2025 [cited by applicant]
US 20250248930A1 · Meyer · 2025 [cited by applicant]
US 20250248931A1 · Meyer · 2025 [cited by applicant]
CA 2780043A1 · 2011 [cited by applicant]
CN 101463009A · 2009 [cited by applicant]
CN 101969940A · 2011 [cited by applicant]
EP 0258865A2 · 1988 [cited by applicant]
WO WO1995005188A1 · 1995 [cited by applicant]
WO WO1999007353A1 · 1999 [cited by applicant]
WO WO2001019364A1 · 2001 [cited by applicant]
WO WO2001085171A1 · 2001 [cited by applicant]
WO WO2004000219A2 · 2003 [cited by applicant]
WO WO2005123093A2 · 2005 [cited by applicant]
WO WO2007008666A2 · 2007 [cited by applicant]
WO WO2009077736A2 · 2009 [cited by applicant]
WO WO2009111418A2 · 2009 [cited by applicant]
WO WO20100135731A1 · 2010 [cited by applicant]
WO WO2011050018A1 · 2011 [cited by applicant]
WO WO2011050030A1 · 2011 [cited by applicant]
WO WO2011127196A1 · 2011 [cited by applicant]
WO WO2012075319A2 · 2012 [cited by applicant]
WO WO2012112566A1 · 2012 [cited by applicant]
WO WO2012119059A1 · 2012 [cited by applicant]
WO WO2012119070A2 · 2012 [cited by applicant]
WO WO2013071138A1 · 2013 [cited by applicant]
WO WO2013078554A1 · 2013 [cited by applicant]
WO WO2013115844A1 · 2013 [cited by applicant]
WO WO2013130577A2 · 2013 [cited by applicant]
WO WO2014121027A1 · 2014 [cited by applicant]
WO WO2014121028A1 · 2014 [cited by applicant]
WO WO2018033792A2 · 2018 [cited by applicant]
WO WO2019018749A1 · 2019 [cited by applicant]
WO WO2019150341A1 · 2019 [cited by applicant]
WO WO2020033714A1 · 2020 [cited by applicant]
WO WO2020072971A1 · 2020 [cited by applicant]
WO WO2020226915A1 · 2020 [cited by applicant]
WO WO2020252057A1 · 2020 [cited by applicant]
WO WO2020252061A1 · 2020 [cited by applicant]
WO WO2022169959A1 · 2022 [cited by applicant]
WO WO2023114347A1 · 2023 [cited by applicant]
Abad et al., “Comparison of Astigmatism Correction Using Shorter Arc Length 90° / 120° Asymmetric Intacs Severe Keratoconus Versus 150° Single-Segment Intacs Severe Keratoconus in Asymmetric Keratoconus,” [cited by applicant]
ACETADOTE® Prescribing Information. [cited by applicant]
ACULAR® Prescribing Information. [cited by applicant]
Asa, “K-max Plus”, retrieved from http://califasainc.com/pdf/Kmax_Analysis.pdf on May 29, 2016. [cited by applicant]
BETAGAN® Prescribing Information. [cited by applicant]
Benson et al., “Is Phentolamine Stable in Solution with Papaverine,” [cited by applicant]
CLARINEX® Prescribing Information. [cited by applicant]
Hadzija et al., “Physicochemical Stability of Papaverine Hydrochloride-Phentolamine Mesylate Mixtures Used for Intracavernous Injection: A Preliminary Evaluation,” [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority, the U.S. Patent & Trademark Office, for International Application No. PCT/US2014/014067, dated May 21, 2014, 8 pages. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority, the U.S. Patent & Trademark Office, for International Application No. PCT/US2014/014070, dated Apr. 15, 2014, 10 pages. [cited by applicant]
Martell, A.E. “Chelates of Ascorbic Acid Formation and Catalytic Properties,” Advances in Chemistry, vol. 200, pp. 153-187 (1982). [cited by applicant]
MUCOMYST® Prescribing Information. [cited by applicant]
OraVerse (phentolamine mesylate) Injection, Prescribing Information, 2 pages. [cited by applicant]
Safety Data Sheet for D-mannitol, by CCI (year 2012). [cited by applicant]
Safety Data Sheet for glycerol, by CCI (year 2012). [cited by applicant]
Soli et al., “Vasoactive Cocktails for Erectile Dysfunction: Chemical Stability of PGE1, Papaverine and Phentolamine,” [cited by applicant]
Troy et al., “Remington: The Science and Practice of Pharmacy”, 21st ed., University of the Sciences, Philadelphia, Pennsylvania, 2006, p. 1032. [cited by applicant]
Tu et al., “Stability of papaverine hydrochloride and phentolamine mesylate in injectable mixtures,” [cited by applicant]
Wang et al., “Degradation Kinetics of Phentolamine Hydrochloride in Solution,” [cited by applicant]
Vivacy, “Stylage”, retrieved from http://www.stylage.eu/technology.html on May 27, 2016. [cited by applicant]
Abelson, et al., A. “The Truth about Tachyphylaxis”, Review of Ophthalmology, (2006), vol. 13, No. 3, pp. 112-115. [cited by applicant]
Johnston, C. “Relief for Patients Troubled by Night-Vision Complaints: Presented at AAO”, PeerVoice Publication, dated Oct. 21, 2010. [cited by applicant]
Murphy et al., “How red is white eye? Clinical grading of normal conjunctival hyperemia”, May 2007, Eye, vol. 21, No. 4, pp. 633-638. [cited by applicant]
National Institutes of Health, “Visual acuity test”, Feb. 23, 2015, online://medlineplus.gov/ency/article/003396.htm, 3 pages. [cited by applicant]
European Search Report dated Jun. 21, 2016 from European Patent Application 14746208.9 (6 pages). [cited by applicant]
Examination Report dated Jan. 31, 2018 from European Patent Application 14746208.9 (6 pages). [cited by applicant]
Notice of Intention to Grant a Patent dated Apr. 10, 2019 from European Patent Application 14746208.9 (162 pages). [cited by applicant]
Doughty, M.J. and Lyle, W. M. “A review of the clinical pharmacokinetics of pilocarpine, moxisylyte (thymoxamine), and dapiprazole in the reversal of diagnostic pupillary dilation,” [cited by applicant]
Hara, H. et al., “Bunazosin, a Selective α [cited by applicant]
Hogan, T. S. et al. “Dose-response study of dapiprazole HCl in the reversal of mydriasis induced by 2.5% phenylephrine,” [cited by applicant]
Rev-Eyes™, in Physicians' Desk Reference for Ophthalmic Medicines (2003) Thomson PDR, p. 258. [cited by applicant]
“Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis”, a clinical study description, available from clinicaltrials.gov online on Jul. 18, 2019. [cited by applicant]
“Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis”, a clinical study description, available from clinicaltrials.gov online on Oct. 14, 2019. [cited by applicant]
“Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma”, a clinical study description, available from clinicaltrials.gov online on Oct. 14, 2019. [cited by applicant]
“Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances”, a clinical study description, available from clinicaltrials.gov online on May 23, 2019. [cited by applicant]
“Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances”, a clinical study description, available from clinicaltrials.gov online on Oct. 14, 2019. [cited by applicant]
“Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances” a clinical study description, available from clinicaltrials.gov online on Aug. 1, 2019. [cited by applicant]
Anastasi, L. M. et al., “Effect of Pilocarpine in Counteracting Mydriasis,” [cited by applicant]
Barbee, R. F. and Smith, W. O. “A Comparative Study of Mydriatic and Cycloplegic Agents: in Human Subjects Without Eye Disease,” [cited by applicant]
Batawi, H. and Micieli, J. A. “Adie's tonic pupil presenting with unilateral photophobia successfully treated with dilute pilocarpine,” [cited by applicant]
Cohen, D. N. and Zakov, A. N. “The Diagnosis of Adie's Pupil Using 0.0625% Pilocarpine Solution,” [cited by applicant]
Doughty, M. J. and Lyle, W. M. “A Review of the Clinical Pharmacokinetics of Pilocarpine, Moxisylyte (Thymoxamine), and Dapiprazole in the Reversal of Diagnostic Pupillary Dilation,” [cited by applicant]
Drummond, P. D. “The Effect of Light Intensity and Dose of Dilute Pilocarpine Eyedrops on Pupillary Constriction in Healthy Subjects,” [cited by applicant]
Edgar, D. F. et al., “Effects of dipivefrin and pilocarpine on pupil diameter, automated perimetry and LogMAR acuity,” Graefe's [cited by applicant]
Gambill, H. D. et al., “Mydriatic Effect of Four Drugs Determined With Pupillograph,” [cited by applicant]
Geyer, O. et al., “The additive miotic effects of dapiprazole and pilocarpine,” [cited by applicant]
Gilmartin, B. et al., “Reversal of tropicamide mydriasis with single instillations of pilocarpine can induce substantial pseudo-myopia in young adults,” [cited by applicant]
Jacobson, D. M. and Olson, K. A. “Influence of Pupil Size, Anisocoria, and Ambient Light on Pilocarpine Miosis: Implications for Supersensitivity Testing,” [cited by applicant]
Leavitt, J. A. et al., “Pupillary Response to Four Concentrations of Pilocarpine in Normal Subjects: Application to Testing for Adie Tonic Pupil,” [cited by applicant]
Muftuoglu, O. et al., “Drug-induced intraocular lens movement and near visual acuity after AcrySof intraocular lens implantation,” [cited by applicant]
Ozulken, K. et al., “Effect of topical pilocarpine on refractive surgery outcomes,” [cited by applicant]
Ramsay, D. A. “Dilute Solutions of Phenylephrine and Pilocarpine in the Diagnosis of Disordered Autonomic Innervation of the Iris: Observations in Normal Subjects, and in the Syndromes of Horner and Holmes-Adie,” [cited by applicant]
Smith, S. A. et al., “An increased effect of pilocarpine on the pupil by application of the drug in oil,” [cited by applicant]
Thompson, H. S. “Adie's Syndrome: Some New Observations,” [cited by applicant]
Zimmerman, T. J. “Pilocarpine,” [cited by applicant]
Dungan, K.W. et al., “Amidephrine-l: Pharmacologic Characterization of a Sympathomimetic Alkylsulfonamidophenethanolamine,” [cited by applicant]
Bill Lloyd, WebMD, Sep. 28, 2007. (Year: 2007). [cited by applicant]
Abdelkader, A. and Kaufman, H. E., “Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia,” [cited by applicant]
Ackerman, S.L. et al., “Low-dose brimonidine for relief of ocular redness: Integrated analysis of four clinical trials,” [cited by applicant]
Akutsu, H. et al., “Contrast Sensitivity and Reading Through Multifocal Intraocular Lenses,” [cited by applicant]
Al-Khersan, H. et al., “Retinal Detachments Associated With Topical Pilocarpine Use for Presbyopia,” [cited by applicant]
Alio, J.L., and Azar, D.T., “Management of Complications in Refractive Surgery,” [cited by applicant]
Amarikwa, L. et al., “Vitreofoveal Traction Associated With Pilocarpine for Presbyopia,” [cited by applicant]
American Optometric Association. Adult Vision: 41 to 60 Years of Age (2022). [cited by applicant]
American Society of Health System Pharmacists; AHFS Drug Information 2010. Bethesda, MD, p. 1386 (2010). [cited by applicant]
Antonelli-Incalzi, R. and Pedone, C., “Respiratory effects of beta-adrenergic receptor blockers,” [cited by applicant]
Applegate, R.A. et al., “Metrics of retinal image quality predict visual performance in eyes with 20/17 or better visual acuity,” [cited by applicant]
Bellucci, R. et al., “Visual acuity and contrast sensitivity comparison between Tecnis and Acrysof AS60 AT intraocular lenses,” [cited by applicant]
Besada, E. et al., “Pupillometry Study of Brimonidine Tartrate 0.2% and Apraclonidine 0.5%,” [cited by applicant]
Betoptic Pilo PI (2006). [cited by applicant]
Bidgoli, S.and Alio, J.L., “Night Vision Disturbances Following Refractive Surgery: Causes, Prevention, and Treatment,” (2018). [cited by applicant]
Boger, W.P. et al., “Clinical Trial Comparing Timolol Ophthalmic Solution to Pilocarpine in Open-Angle Glaucoma,” [cited by applicant]
Boland, M.V. et al., “Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study,” [cited by applicant]
Boyer, D. et al., “Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials,” ASRS Annual Meeting, Abstract ID 665511 (2022). [cited by applicant]
Bradley, A.E. et al., “International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Nonproliferative and Proliferative Lesions of the Rabbit,” [cited by applicant]
British Journal of Ophthalmology, European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition—Chapter 3: “Treatment Principles and Options.” [cited by applicant]
Brooks et al., “Patient subjective visual function after corneal collagen crosslinking for keratoconus and corneal ectasia,” [cited by applicant]
Bruner, R.H. et al., “Spontaneous hibernomas in Sprague-Dawley rats,” [cited by applicant]
Brunton, L. et al., “Goodman & Gilman's Pharmacological Basis of Therapeutics, 12e,” [cited by applicant]
Büscher, R. et al., “Comparison of guinea-pig, bovine and rat alpha 1-adrenoceptor subtypes,” [cited by applicant]
Cankurtaran, V. and Tekin, K., “Effects of a Single Dose of Topical Brimonidine 0.15% on Anterior Segment Morphology, Pupil Characteristics, and Choroidal Thickness in Healthy Subjects,” [cited by applicant]
Canovetti, A. et al., “Aceclidine, brimonidine tartrate, and dapiprazole: Comparison of miotic effect and tolerability under different lighting conditions,” [cited by applicant]
CDRH FDA Tecnis Multifocal IOL: P080010: CDRH/FDA, “Summary of Safety and Effectiveness,” (2009)https://www.accessdata.fda.gov/cdrh_docs/pdf8/P080010B.pdf. [cited by applicant]
CDRH/FDA, “Summary of Safety and Effectiveness of VISX STAR Excimer Laser System,” (2007). [cited by applicant]
Chu, Y.R. et al., “The Safety of Phentolamine Ophthalmic Solution for Reversal of Pharmacologically Induced Mydriasis from Multiple Late-Stage Clinical Trials,” ASCRS Annual Meeting, Paper ID 80618 (2022). [cited by applicant]
Chylak, L. T. et al., “Loss of contrast sensitivity in diabetic patients with LOCSII classified cataracts,” [cited by applicant]
Csaky, K.G. et al., “Report from the NEI/FDA ophthalmic clinical trial design and endpoints symposium,” [cited by applicant]
Dart, R.C., [cited by applicant]
De La Torre, J.C. et al., “Impaired Cerebromicrovascular Perfusion,” [cited by applicant]
Deeb, S.E. et al., “Evaluation of monolithic C18 HPLC columns for the fast analysis of pilocarpine hydrochloride in the presence of its degradation products,” [cited by applicant]
Degraff, A.C. et al., “Phentolamine,” [cited by applicant]
Devries, D. et al., “Phentolamine Ophthalmic Solution Reverses Pharmacologically Induced Mydriasis in Healthy Subjects: Subgroup Analyses in the Pivotal Phase 3 MIRA-2 Randomized Placebo Controlled Trial,” ARVO Annual M… [cited by applicant]
Dexl, A.K. et al., “Reading performance after implantation of a small-aperture corneal inlay for the surgical correction of presbyopia: Two-year follow-up,” [cited by applicant]
Dick, H.B. et al., “Contrast sensitivity after implantation of toric iris-claw lenses in phakic eyes,” [cited by applicant]
Diestelhorst, M. et al., “Combined Therapy of Pilocarpine or Latanoprost with Timolol Versus Latanoprost Monotherapy,” [cited by applicant]
Dinsmore, W.W. and Alderdice, D.K., “Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal age… [cited by applicant]
Dragoi, V., “Ocular Motor System. In: Neuroscience Online: An Electronic Textbook for the Neurosciences,” The University of Texas Health Science Center at Houston (2020). [cited by applicant]
Draize, J.H. et al., “Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes,” [cited by applicant]
Draize, J.H., “Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics,” [cited by applicant]
Drews-Bankiewiez, M. et al., “Contrast Sensitivity in Patients with Nuclear Cataracts,” [cited by applicant]
Drugbank Online, “Phentolamine” https://go.drugbank.com/drugs/DB00692 Accessed Aug. 25, 2022. [cited by applicant]
Drum, B. et al., “Assessment of visual performance in the evaluation of new medical products,” In: [cited by applicant]
Du, H. et al., “Cell membrane chromatography competitive binding analysis for characterization of a1A adrenoreceptor binding interactions,” [cited by applicant]
Durand-Cavagna, G. et al., “Spontaneous pre- Descemet's membrane corneal opacities in rabbits,” [cited by applicant]
Elliott, D.B. et al., “Improvements in clinical and functional vision and perceived visual disability after first and second eye cataract surgery,” [cited by applicant]
Elliott, D.B. et al., “The reliability of the Pelli-Robson chart,” [cited by applicant]
Enroth-Cugell et al., “The contrast sensitivity of retinal ganglion cells of the cat.,” [cited by applicant]
Eton, E.A. et al., “Rhegmatogenous Retinal Detachment Following Initiation of Pilocarpine Hydrochloride Ophthalmic Solution 1.25% for Treatment of Presbyopia,” [cited by applicant]
European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition—Chapter 3, “Treatment principles and options,” [cited by applicant]
Eydelman, M. et al., “Symptoms and Satisfaction of Patients in the Patient-Reported Outcomes With Laser In Situ Keratomileusis (PROWL) Studies,” [cited by applicant]
Fan, T.Y. et al., “Improved high-performance liquid chromatographic determination of pilocarpine and its degradation products in ophthalmic solutions importance of octadecylsilane col. choice,” [cited by applicant]
Fan-Paul, N. et al., “Night vision disturbances after corneal refractive surgery,” [cited by applicant]
Fejer, T.P. et al., “Night myopia: implications for the young driver,” [cited by applicant]
Foster, S. et al., “MIRA-4, Clinical Trial Evaluating the Safety and Efficacy of Phentolamine Ophthalmic Solution for Reversal of Pharmacologically Induced Mydriasis in Pediatric Subjects Aged 3-11 Years,” AAOpt Annual … [cited by applicant]
Fricke, T. R. et al., “Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia: Systematic Review, Meta-analysis, and Modelling,” [cited by applicant]
Ginsburg, A.P., “Contrast sensitivity and functional vision in Functional Vision,” In Packer, M, editor. [cited by applicant]
Ginsburg, A.P., “Contrast sensitivity: determining the visual quality and function of cataract, intraocular lenses and refractive surgery,” [cited by applicant]
Ginsburg, A.P., “Vision Channels, Contrast Sensitivity and Functional Vision in Human Vision and Electronic Imaging IX,” Rogowitz, BE, ed. SPIE-IS&T, 529:215-25 (2004). [cited by applicant]
Giovannitti, J.A., Jr et al., “Alpha-2 adrenergic receptor agonists: a review of current clinical applications,” [cited by applicant]
Godbillon J., “Determination of the major metabolite of phentolamine in human plasma and urine by high performance liquid chromatography,” [cited by applicant]
Goel, M. et al., “Aqueous humor dynamics: a review,” [cited by applicant]
Goertz, A.D. et al., “Review of the impact of presbyopia on quality of life in the developing and developed world,” [cited by applicant]
Goldstein, I., “Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction,” [cited by applicant]
Gomez-Gomar, A. et al., “HPLC method for the simultaneous determination of pilocarpine, isopilocarpine, pilocarpic acid and isopilocarpic acid,” [cited by applicant]
Hays, R.D. et al., “Assessment of the Psychometric Properties of a Questionnaire Assessing Patient-Reported Outcomes With Laser In Situ Keratomileusis (PROWL),” [cited by applicant]
Hersh, E.V. et al., “Phase Four, Randomized, Double-Blinded, Controlled Trial of Phentolamine Mesylate in Two- to Five-year-old Dental Patients,” [cited by applicant]
Hersh, E.V. et al., “Phentolamine mesylate for accelerating recovery from lip and tongue anesthesia,” [cited by applicant]
Hill, C.E. et al., “Specificity of innervation of iris musculature by sympathetic nerve fibres in tissue culture,” [cited by applicant]
Holladay, J.T. et al., “Functional vision and corneal changes after laser in situ keratomileusis determined by contrast sensitivity, glare testing and corneal topography,” [cited by applicant]
Holladay, J.T. et al., “Phentolamine Mesylate Ophthalmic Solution Once Daily Reduces Pupil Diameter and Improves Night Vision Disturbances,” AAO Annual Meeting, PA025 (2018). [cited by applicant]
Holve, D., “Optical Coherence Tomography and Slit Lamp Imaging of Corneal Dystrophy in the Dutch Belted Rabbit,” Unpublished data. [cited by applicant]
Hong, D., “Tropicamide,” [Updated Jul. 4, 2020]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2020). [cited by applicant]
Howe, J.W., “The objective assessment of contrast sensitivity function by electrophysiological means,” [cited by applicant]
Ishikawa, H. et al., “Comparison of post-junctional alphaadrenoceptors in iris dilator muscle of humans, and albino and pigmented rabbits,” [cited by applicant]
Isopto, Isopto® Carpine (Pilocarpine Hydrochloride Ophthalmic Solution) FDA Documents 1%, 2% and 4%. Highlights of Prescribing Information (2010). [cited by applicant]
Israilov, S. et al., “Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate,” [cited by applicant]
Jackson, M. et al., “A Combination of Phentolamine Eye Drops and Low Dose Pilocarpine Improves Near Vision in VEGA-1 Phase 2 Presbyopia Trial,” AAO (2022). [cited by applicant]
Jin, B. et al., “Degradation Characteristics of a Novel PAF Receptor Antagonist, SY0916, in Aqueous Solution.” [cited by applicant]
Kan, X., “UPLC-MS/MS Determination of Phentolamine in Human Plasma and its Application to a Pharmacokinetic Study,” [cited by applicant]
Kannarr, S. et al., “LYNX-1: A Pivotal Phase 3 Randomized Placebo-Controlled Trial of Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbance,” AAOpt Annual Meeting, Abstract ID 10526 (2022). [cited by applicant]
Karpecki, P.M. et al., “Phentolamine eye drops reverse pharmacologically induced mydriasis in a randomized phase 2b trial,” [cited by applicant]
Kass, M A. et al., “The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma,” [cited by applicant]
Kato, C.O.S. et al., “Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex,” [cited by applicant]
Katz, J. et al., “ VEGA-1: Phentolamine Ophthalmic Solution as a Single Agent Improves Distance-Corrected Near Visual Acuity in Patients with Presbyopia,” ARVO Annual Meeting, Abstract ID 3712883 (2022). [cited by applicant]
Kennedy, “High-performance liquid chromatographic analysis of pilocarpine hydrochloride, isopilocarpine, pilocarpic acid and isopilocarpic acid in eye-drop preparations,” [cited by applicant]
Kerger, B.D. et al., “An assay for phentolamine using high performance liquid chromotography with electrochemical detection,” [cited by applicant]
Kesler A. et al., “Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size,” [cited by applicant]
Kiel, J.W. and Reitsamer, H.A., “Paradoxical effect of phentolamine on aqueous flow in the rabbit,” [cited by applicant]
Kimlin, J.A. et al., “Nighttime Driving in Older Adults: Effects of Glare and Association With Mesopic Visual Function,” [cited by applicant]
Kinney, M., “Temporal Effects of 2% Pilocarpine Ophthalmic Solution on Human Pupil Size and Accommodation,” [cited by applicant]
Kirsten, R. et al., “Clinical pharmacokinetics of vasodilators. Part II,” [cited by applicant]
Klein, B.E. et al., “Prevalence of glaucoma. The Beaver Dam Eye Study,” [cited by applicant]
Kobayashi, H. et al., “Efficacy of bunazosin hydrochloride 0.01% as adjunctive therapy of latanoprost or timolol,” [cited by applicant]
Konno, F. and Takayanagi, I., “Characterization of postsynaptic alpha-1 adrenoceptors in the rabbit iris dilator smooth muscle,” [cited by applicant]
Koss, M.C., & Gherezghiher, T., “Pharmacological characterization of alphaadrenoceptors involved in nictitating membrane and pupillary responses to sympathetic nerve stimulation in cats,” [cited by applicant]
Krupin, T. et al., “Effect of prazosin on aqueous humor dynamics in rabbits,” [cited by applicant]
Kupersmith, M.J. et al., “Contrast sensitivity loss in multiple sclerosis,” [cited by applicant]
Kwon, Y.H. et al., “Primary open-angle glaucoma,” [cited by applicant]
Lai, J.S. et al., “The efficacy and safety of combined phacoemulsification, intraocular lens implantation, and limited goniosynechialysis, followed by diode laser peripheral iridoplasty, in the treatment of cataract and… [cited by applicant]
Langevin, N.E. et al., “Historical Data: Histopathology Lesions Observed in the Eyes of Control Rabbits in Topical Ocular Administration and Contact Lens Studies,” [cited by applicant]
Lee, J.H. et al., “Efficacy of brimonidine tartrate 0.2% ophthalmic solution in reducing halos after laser in situ keratomileusis,” [cited by applicant]
Lewis, R.A. et al., “Fixed-dose combination of AR-13324 and latanoprost: A double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension,” [cited by applicant]
Lin et al., “Pharmacokinetics Study of Phentolamine Mesylate Injection in Healthy Volunteers. In Sichuan da xue xue bao. Yi xue ban= [cited by applicant]
Liu, J.C., “Assessing the utility of 2.5% phenylephrine for diagnostic pupillary dilation,” [cited by applicant]
Lograno, M.D. and Reibaldi, A., “Receptor-responses in fresh human ciliary muscle,” [cited by applicant]
Marshall, L.L. et al., “Therapy for Open-Angle Glaucoma.,” [cited by applicant]
Martinez, C.E. et al., “Effect of pupillary dilation on corneal optical aberrations after photorefractive keratectomy,” [cited by applicant]
Marx-Gross, S. et al., “Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels,” [cited by applicant]
Matsuura, K. et al., “Determination of pilocarpine in aqueous humour by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry,” [cited by applicant]
McAuliffe-Curtin, D. and Buckley, C., “Review of alpha adrenoceptor function in the eye, ” [cited by applicant]
McDonald, M. et al., “MIRA-3: A 2nd Phase 3 Randomized Placebo-Controlled Trial of Phentolamine Ophthalmic Solution to Reverse Pharmacologically Induced Mydriasis,” ASCRS Annual Meeting, Paper ID 81993 (2022). [cited by applicant]
McDonald, M.B. et al., “Phentolamine mesylate treatment of severe night-vision complaints,” Presented at: Annual Meeting of the American Society of Cataract and Refractive Surgery; Mar. 25-29, 2011; San Diego, CA. [cited by applicant]
McDonald, M.B. et al., “Phentolamine Mesylate Treatment of Severe Night Vision Complaints,” AAO Abstracts, PO433 (2010). [cited by applicant]
McDonnell, P.J. et al., “Associations of presbyopia with vision-targeted health-related quality of life,” [cited by applicant]
McMahon, C.G., “A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction,” [cited by applicant]
Mittag, T.W. et al., “Alpha-adrenergic antagonists: correlation of the effect on intraocular pressure and on alpha 2-adrenergic receptor binding specificity in the rabbit eye,” [cited by applicant]
Mohammadpour, M. et al., “Updates on Managements for Keratoconus,” [cited by applicant]
Molinari, J.F. et al., “Dapiprazole clinical efficiency for counteracting tropicamide 1%,” [cited by applicant]
Molinari, J.F. et al., in [cited by applicant]
Monestam, E. and Lundqvist, B., “Long-time results and associations between subjective visual difficulties with car driving and objective visual function 5 years after cataract surgery,” [cited by applicant]
Montes-Mico, R. et al., “Choice of spatial frequency for contrast sensitivity evaluation after corneal refractive surgery,” [cited by applicant]
Montes-Mico, R. et al., “Visual performance with multifocal intraocular lenses: Mesopic contrast sensitivity under distance and near conditions,” [cited by applicant]
Moore, C.P. et al., “Anterior Corneal Dystrophy of American Dutch Belted Rabbits: Biomicroscopic and Histopathologic Findings,” [cited by applicant]
Moore, P.A. et al., “Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate,” In [cited by applicant]
Motolko, M.A. and Phelps, C.D., “Contrast sensitivity in asymmetric glaucoma,” [cited by applicant]
Nagasubramanian, S.A., “Comparison of the Ocular Hypotensive Efficacy, Safety and Acceptability of Brimonidine 0.2% Twice Daily Versus Pilocarpine 2.0% Thrice Daily as Adjunct Therapy with Beta-Blockers,” In: [cited by applicant]
Nakamura, S. et al., “Evaluation of alpha-1 adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA,” [cited by applicant]
National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 517293, Phentolamine, methane sulfonate. [cited by applicant]
National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 91430, Phentolamine mesylate. [cited by applicant]
National Institutes of Health. “NIH urges dilated eye exams to detect glaucoma,” Accessed Apr. 24, 2020. https://www.nih.gov/news-events/news-releases/nih-urges-dilated-eye-exams-detect-glaucoma. [cited by applicant]
Neonatal Intensive Care, Children's Hospital, Neonatal Intensive Care Unit, May 26, 2011. [cited by applicant]
Nielsen, C.B. and Nielsen, P.J., “Effect of alpha- and beta-receptor active drugs on corneal thickness,” [cited by applicant]
Noordam, A. et al., “Quantitative Determination of Pilocarpine, Isopilocarpine, Pilocarpic Acid, and Isopilocarpic Acid in Clinical Ophthalmic Pilocarpine Formulations by Reversed-Phase Liquid Chromatography,” [cited by applicant]
Nyman, N., Optometrist*; Keates, Edwin U. “Physician†. Effects of Dapiprazole on the Reversal of Pharmacologically Induced Mydriasis,” [cited by applicant]
Ogura, T. et al., “Properties of [3H]bunazosin binding in rat kidney,” [cited by applicant]
OraVerse Summary Basis of Approval (SBA). Clinical pharmacology and biopharmaceutics review. Application No. 22-159; 2007. Novalar. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022159s000_ClinPharmR. [cited by applicant]
OraVerse, “OraVerse (phentolamine mesylate) FDA Documents injection,” Highlights of Prescribing Information. Septodont (2016a). [cited by applicant]
OraVerse, OraVerse FDA Documents. FDA approves OraVerse for pediatric dental patients 3 years and older. Septodont (2016b). [cited by applicant]
Oshika, T. et al., “Effect of bunazosin hydrochloride on intraocular pressure and aqueous humor dynamics in normotensive human eyes,” [cited by applicant]
Oshika, T. et al., “Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist,” [cited by applicant]
Owsley, C. and Sloane, M.E., “Contrast sensitivity, acuity, and the perception of ‘real-world’ targets,” [cited by applicant]
Owsley, C., “Contrast Sensitivity,” [cited by applicant]
Padma-Nathan, H. et al., “Long-term safety and efficacy of oral phentolamine mesylate (Vasomax) in men with mild to moderate erectile dysfunction,” [cited by applicant]
Park, S.Y. et al., “Clinical Efficacy of Pinhole Soft Contact Lenses for the Correction of Presbyopia,” [cited by applicant]
Pepose, J. (2021c), “Phase 2 Clinical Trial To Evaluate The Efficacy Of Phentolamine Ophthalmic Solution And Low-Dose Pilocarpine For The Treatment Of Presbyopia,” AAO Annual Meeting. Abstract ID 30068457. [cited by applicant]
Pepose, J. et al. (2022a), “Phentolamine Ophthalmic Solution as a Single Agent Improves Distance-Corrected Near Visual Acuity in Patients with Presbyopia,” ASCRS Annual Meeting, Paper ID 80665. [cited by applicant]
Pepose, J. et al. (2022b), “VEGA-1: Phentolamine Ophthalmic Solution in combination with Low Dose Pilocarpine Improves Distance-Corrected Intermediate Visual Acuity in Patients with Presbyopia,” ARVO Annual Meeting, Abs… [cited by applicant]
Pepose, J., et al., “A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances,” [cited by applicant]
Pepose, J.P. et al., “Phentolamine mesylate ophthalmic solution provides long lasting pupil modulation and improves visual acuity,” The Association for Research in Vision and Ophthalmology Meeting (2020). [cited by applicant]